Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Selinexor
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Karyopharm Therapeutics Inc